Multiple Myeloma

There is a significant efficacy-effectiveness gap in standard-of-care regimens.

Presentations detail clinical trial results and focus on drugs in the pipeline.

2023 was an impactful year for the field of oncology pharmacy.

Not only were individuals with BMIs of 30 and higher likely to have MGUS, but those who reported heavy smoking and short sleep were also more likely to have detectable levels of MGUS.

The study results also demonstrated isatuximab had safety and tolerability profiles that were consistent with other clinical trials.

These data support the combination of daratumumab plus VRd followed by daratumumab and lenalidomide maintenance as a new standard of care for transplant-eligible patients.

Seven new agents have received FDA approval since October 2022.

The efficacy of treatments, which is the outcomes in the ideal clinical trial setting, are known to often be better than the effectiveness of those treatments, which are the outcomes of patients in the real-world setting.

Belantamab mafodotin (Blenrep; GlaxoSmithKline) demonstrated that, when combined with bortezomib and dexamethasone (BorDex), the time to disease progression or death was extended.

The review comes after phase 3 trial results that indicate an improvement in overall survival and progression-free survival, reducing the risk of disease progression and death.

The study authors suggest that future research should instead emphasize event rates and patient-reported outcomes to better evaluate the tolerability and frequency of AEs.

The study findings provide the first in-depth look at the relationship between chromosomal changes in tumor cells and immune components of the tumor microenvironment.

Intravenous immunoglobulin could potentially be given throughout the duration of anti-BCMA bispecific antibody therapy for the treatment of multiple myeloma.

Most patients had improved clinical response within 90 days of receiving the dendritic cell vaccine and ASCT.

Bispecific antibodies have 2 distinct binding domains, which interact with either CD3 on T cells or a tumor-associated antigen on the tumor cell surface.

Bispecific antibodies have offered a new treatment approach in relapsed/refractory multiple myeloma, with promising results in preclinical studies for multiple cancers and hematological malignancies.

Mezigdomide boosted T cell activity and worked in patients with multiple myeloma who were resistant to prior therapeutic agents.

During the phase 1b/2 trials, CAR T-cell therapy demonstrated significant and clinical survival benefits.

Elranatamab-bcmm (Elrexfio; Pfizer) is a BCMA-CD3-targeted bispecific antibody approved for adults with relapsed or refractory multiple myeloma who were previously administered at least 4 lines of therapy that included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Talquetamab-tgvs (Talvey) is a first-in-class bispecific antibody that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing multiple myeloma cells.

Drs Haumschild, Anderson, and Hinojosa provide their closing thoughts regarding treatment considerations for patients with RRMM.

Navigating treatment toxicities is paramount to achieving treatment goals in MM management.

The medical experts discuss strategies to achieve treatment adherence.

Social determinants of health inhibit optimal impact of MM treatment.

Multiple myeloma clinical pathways and factors affecting patient quality of life are explored by an expert panel.